RegMed Investors’ (RMi) pre-open: Key word, anticipate

March 18, 2022 7:27am

The probable - it’s market’s optimism versus sector’s pessimism

I am not comfortable in non-news or fundamental and electronic sector moves, there are always issues lurking that could erase share appreciations; it pays to be an early event orienteered

Pre-open indications: 9 SELLs, 3 BUYs indications and 1 pimp/pump/promote

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Just the facts … I ask questions and note the indications of what could happen …

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

Dow futures are DOWN -0.65% (-225 points), S&P futures are DOWN -0.75% (-33 points) and NASDAQ futures are DOWN -0.76% (-108 points)

Stock futures are falling in the early pre-open on Friday following a three-day rally,

European markets were flat,

Asia-Pacific markets were mixed, with Hong Kong’s Hang Seng index continuing to exhibit wild volatility amid a rollercoaster week.

Henry’omics:

All three major indexes advanced more than 1% on Thursday as investors considered the Fed's interest rate hikes and worries eased on top of prospects of any other Russian defaults.

The Dow is coming off a four-day winning streak, rising 4.7% for the week so far, and is also on pace for its biggest weekly gain since November 2020.

The Nasdaq Composite is up 6% this week, headed for its best week since February 2021.

The S&P 500 has gained for three consecutive days this week, up 4.9%, on track for its best week since November 2020.

RegMed Investors’ (RMi) closing bell: “Algorithmic tailwinds are pushing the cell and gene therapy sector upward.” … https://www.regmedinvestors.com/articles/12346

Ebb and flow –

·         March – 7 negative and 6 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes

Research Notes:

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ...  26 total

Companies in my headlights – It’s your decision; I provide ideas and context:

SELL into Strength:

Alnylam Pharmaceuticals (ALNY closed up +$4.11 after Wednesday’s +$6.05, Tuesday’s +$1.12 and Monday’s -$3.16 with a positive +$2.55 or +1.56% pre-open indication.

Editas Medicine (EDIT) closed up +$1.11 after Wednesday’s +$1.25, Tuesday’s +$0.83 and Monday’s -$0.98 with a positive +$0.07 or +0.41% pre-open indication.

Maintaining SELL into Strength:

Sage Therapeutics (SAGE) closed up +$0.44 to $33.90 after Wednesday’s +$2.09 and Tuesday’s +$0.66 with a negative -$0.25 or -0.74% pre-open indication.

SELL:

CRISPR Therapeutics (CRSP) closed up +$1.92 to $67.46 after Wednesday’s +$5.50, Tuesday’s +$1.98 and Monday’s -$3.36 with a negative -$0.46 or -0.68% pre-open indication.

Intellia Therapeutics (NTLA) closed up =$3.13 to $69.05 after Wednesday’s +$7.65 to $65.92, Tuesday’s -$0.53 to 458.27, Monday’s -$2.49 to $58.80 and last Friday’s-$4.62 to $61.29 with a negative -$1.06 or -1.54% pre-open indication.

Fate Therapeutics (FATE) closed up +$2.02 to $36.07 after Wednesday’s +$2.74, Tuesday’s +$1.64 and Monday’s -$3.88 with a negative -$2.22 or -6.155 pre-open indication.

BioLife Solutions (BLFS) closed up +$1.43 to $22.93 after Wednesday’s +$0.15 with a negative -$1.58 or -6.89% pre-open indication. Questions surrounds WHY - additional delay in the filing of its Annual Report on Form 10-K for the year ended December 31, 2021?

uniQure NV (QURE) closed up +$1.21 to $17.10 after Wednesday’s +$0.82 with a negative -$1.49 or -8.71% pre-open indication

BUY:

AxoGen (AXGN) closed up +$0.92 to $9.12 with a positive +$0.88 or +9.65% pre-open indication.

Global Blood Therapeutics (GBT) closed up +$1.06 to $31.19 after Wednesday’s +$1.28 with a positive +$0.76 or +2.44% pre-open indication.

Ionis Pharmaceuticals (IONS) closed up +$0.78 to $34.76 after Wednesday’s +$1.28 to $33.98 with a positive +$0.44 or +1.27% pre-open indication

SELL from BUY

Beam Therapeutics (BEAM) closed up +$2.45 to $62.29 after Wednesday’s +$4.60 to $59.84, Tuesday’s +$1.51 to $55.24, Monday’s -$7.18 to $53.73 and last Friday’s -$4.81 to $60.91 with a negative -$0.34 or -0.55% pre-open indication.

Pimp/Pump and Promote:

Biostage (OTCQB: BSTG) closed up +$0.47 with 1,737 shares traded after Wednesday’s flat with 765 shares traded, Tuesday’s -$0.30 to $4.00 with 380 shares traded, Monday’ 28 shares traded and last Friday’s +$0.39 to $4.30 with 1,602 shares traded …

• WHO is BUYING these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
• Also, by use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering …
• BSTG is NOT going ANYWHERE without a cash infusion.

The BOTTOM LINE: After a three (3) session rally are you as an investor willing to wait-it-out for the falling knife?

It’s coming …

This market remains at the mercy of the latest headline as war and killing news is the bane of March lifting or sinking the major indexes.

There are still plenty of hurdles i.e., further earnings release - another eight (8) are due.

I believe many of the oversold show buy signals but very likely will reverse lower.

There is no clear trend, and no reason to make any BUYS - however, the better way of saying but … short-term pops are (to me) clearly evident.

As I have stated yesterday, “bounce, baby, bounce”.

Earnings’ reporting on the horizon:

·         Brainstorm Cell Therapeutics (BCLI), Monday, 3/28

Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider their investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.

WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it defines purpose that takes courage, resolve and patience to stay the course of asking the questions without response!